• Moderna’s investigational Bundibugyo ebolavirus vaccine, mRNA-1469, was recommended to advance into the Phase 2/3 Tumaini efficacy trial in the Democratic Republic of Congo.
• The recommendation followed a WHO advisory group’s October 22 review; trial participation remains subject to regulatory approval.
• Reported interim Phase 1 results showed the vaccine was generally well tolerated, with a single dose generating strong virus-specific antibody responses.
• CEPI has committed up to US$58.5 million for vaccine development and trial-dose manufacturing, with separate funding for Tumaini.
• No vaccine is currently licensed specifically to prevent Bundibugyo virus disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611041105ACCESSWRNAPR_____1246308) on November 04, 2026, and is solely responsible for the information contained therein.